A very interesting question at Slashdot: “To what extent do the traditional contours of patent law need to change in response to new technologies with a different set of market realities (biotech drugs are 22 times more expensive on average, and development costs for generics will be substantially higher) and in what direction? Need every new technological category get its own patent rules, and how do those rules get decided?”
If rational agents respond to incentives (see below), does a flat incentive approach works on patents?
